Biogen Partners with Proximity Health to Empower Lupus Patients Through Innovative Engagement Initiative
- Biogen collaborates with Proximity Health Solutions on the "Better Together" initiative, enhancing lupus patient engagement and education.
- Tara Aldoory from Biogen highlights the importance of patient perspectives in clinical trials through community-centered initiatives.
- The initiative aims to improve health equity and clinical trial participation among underserved lupus populations.
Empowering Lupus Patients Through Innovative Engagement Initiatives
Proximity Health Solutions, in collaboration with Biogen, gains recognition for its groundbreaking initiative "Better Together: Sharing Our Lupus Stories," which is named a finalist for the 2026 SCOPE Participant Engagement Award. This accolade underscores the innovative design and substantial impact of the webinar series, which aims to enhance the clinical trial experience for patients, particularly focusing on female, African American lupus patients. The series educates participants on the complexities of lupus and emphasizes the critical role that clinical trial participation plays in improving health outcomes. With this initiative, Proximity Health Solutions and Biogen demonstrate a commitment to addressing health disparities in underserved communities.
The webinar series, now in its fifth season, airs on BlackDoctor.Org's Facebook Live platform and boasts impressive engagement metrics, averaging 47,000 views per episode and exceeding one million total views. This level of reach illustrates the initiative's sustainability and effectiveness in fostering a supportive environment for lupus patients. Rick Adler, CEO of Proximity Health Solutions, expresses pride in the recognition, affirming that their mission centers on empowering patients to make informed medical decisions. This initiative serves as a vital resource, providing education and encouraging dialogue around lupus, which is often underrepresented in clinical research.
Tara Aldoory, Head of Quantitative Sciences and Development Operations at Biogen, emphasizes the importance of integrating patient perspectives into the clinical trial process. By creating a community-centered platform, the initiative not only informs patients but also builds trust in the medical community and encourages engagement with clinical trials. Both Proximity Health Solutions and Biogen are committed to transforming patient engagement through innovative educational programs, reinforcing their role in advancing health equity and improving clinical trial participation among underrepresented populations.
In addition to the recognition from the SCOPE Participant Engagement Award, the "Better Together: Sharing Our Lupus Stories" initiative highlights a growing trend in the healthcare industry towards patient-centered education. By prioritizing the voices of patients, especially those from marginalized backgrounds, organizations can better address the unique challenges they face in managing their health conditions.
As the healthcare landscape evolves, initiatives like this reinforce the need for collaborative efforts to enhance patient engagement and foster inclusivity in clinical trials. The SCOPE '26 award winners will be announced at the annual Summit for Clinical Ops Executives in February 2026, marking an important moment for recognizing efforts that significantly impact patient care and participation in clinical research.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…